반응식
[NH:1]([C:13]([O:15]C(C)(C)C)=O)[C@@H:2]([C:10]([OH:12])=O)[CH2:3][C:4]1[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=1.[NH:20](C(OCC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O)[C@@H:21](C(O)=O)[CH2:22][C:23]1[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1.[NH:49]([C:58]([O:60]CC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O)[C@@H:50]([C:55]([OH:57])=[O:56])[CH2:51][CH2:52][CH2:53]C.[NH:75]([C:104]([O:106]CC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O)[C@@H:76](C(O)=O)[CH2:77][CH2:78][CH2:79][NH:80][C:81](=[NH:100])[NH:82]S(C1C(C)=C2C(OC(C2)(C)C)=C(C)C=1C)(=O)=O.[N:121]1(C(OCC2C3C(=CC=CC=3)C3C2=CC=CC=3)=O)[CH2:128][CH2:127][CH2:126][C@@H:122]1[C:123](O)=O>>[NH2:20][C@@H:21]([C:13]([NH:1][C@@H:2]([C:10]([NH:121][C@@H:128]([C:104]([NH:75][C@@H:76]([C:58]([N:49]1[CH2:53][CH2:52][CH2:51][C@@H:50]1[C:55]([OH:57])=[O:56])=[O:60])[CH2:77][CH2:78][CH2:79][NH:80][C:81](=[NH:100])[NH2:82])=[O:106])[CH2:127][CH2:126][CH2:122][CH3:123])=[O:12])[CH2:3][C:4]1[CH:5]=[CH:6][CH:7]=[CH:8][CH:9]=1)=[O:15])[CH2:22][C:23]1[CH:24]=[CH:25][CH:26]=[CH:27][CH:28]=1참가 물질
6
반응물 5
생성물 1
실험 절차
The compound was prepared according to the procedure described in the synthesis of compound (1). The amino acid derivatives used were Boc-D-Phe-OH, Fmoc-D-Phe-OH, Fmoc-D-Nle-OH, Fmoc-D-Arg(Pbf)-OH, and Fmoc-D-Pro-OH. Final purified peptide: amorphous powder, 140 mg in yield in a synthesis scale of 0.3 mmol. HPLC analysis: tR=20.23 min, purity 99.7%, gradient 10% B to 30% B over 20 min; MS (M+H+): expected molecular ion mass 679.4, observed 679.5.
후처리
- customThe compound was prepared
- customFinal purified peptide
- customamorphous powder, 140 mg in yield in a synthesis scale of 0.3 mmol
출처 및 근거
- ORD 기록
- ord-3196bf5c95b3480e8ac001ec7904becb
- 출처 데이터셋
- uspto-grants-2016_05
- 특허 번호
- US09334305B2
연결된 노트
불러오는 중…